OBJECTIVE: The aim of our study was to assess the effect of mammographic parenchymal pattern on patient survival, mammographic features, and pathologic features of breast cancer in a screened population. MATERIALS AND METHODS: We classified the parenchymal pattern (according to BI-RADS) of 759 screened women who presented with a screening-detected (n = 455) or interval (n = 304) invasive breast cancer. Pathologic details (tumor size, histologic grade, lymph node stage, vascular invasion, and histologic type) and mammographic appearances were recorded. Breast cancer-specific survival was ascertained, with a median follow-up of 9.0 years. RESULTS: An excess of interval cancers was seen in women with dense breasts (p < 0.0001). Screening-detected (but not interval) tumors were significantly smaller in fatty breasts (p = 0.014). Tumor grade, lymph node stage, vascular invasion, and histologic type did not vary significantly with mammographic parenchymal pattern in screening-detected or interval cancers. Screening-detected cancers in fatty breasts were more likely to appear as indistinct (p = 0.003) or spiculated (p = 0.002) masses in contrast to cancers in dense breasts, which more commonly appeared as architectural distortions (p < 0.0001). No significant breast cancer-specific survival difference was seen by mammographic parenchymal pattern for screening-detected cancers (p = 0.75), interval cancers (p = 0.82), or both groups combined (p = 0.12). CONCLUSION: The prognosis of screened women presenting with breast cancer is unrelated to dense mammographic parenchymal pattern despite an excess of interval cancers and larger screening-detected tumors in this group. These data support the mammographic screening of women with dense parenchymal patterns.
OBJECTIVE: The aim of our study was to assess the effect of mammographic parenchymal pattern on patient survival, mammographic features, and pathologic features of breast cancer in a screened population. MATERIALS AND METHODS: We classified the parenchymal pattern (according to BI-RADS) of 759 screened women who presented with a screening-detected (n = 455) or interval (n = 304) invasive breast cancer. Pathologic details (tumor size, histologic grade, lymph node stage, vascular invasion, and histologic type) and mammographic appearances were recorded. Breast cancer-specific survival was ascertained, with a median follow-up of 9.0 years. RESULTS: An excess of interval cancers was seen in women with dense breasts (p < 0.0001). Screening-detected (but not interval) tumors were significantly smaller in fatty breasts (p = 0.014). Tumor grade, lymph node stage, vascular invasion, and histologic type did not vary significantly with mammographic parenchymal pattern in screening-detected or interval cancers. Screening-detected cancers in fatty breasts were more likely to appear as indistinct (p = 0.003) or spiculated (p = 0.002) masses in contrast to cancers in dense breasts, which more commonly appeared as architectural distortions (p < 0.0001). No significant breast cancer-specific survival difference was seen by mammographic parenchymal pattern for screening-detected cancers (p = 0.75), interval cancers (p = 0.82), or both groups combined (p = 0.12). CONCLUSION: The prognosis of screened women presenting with breast cancer is unrelated to dense mammographic parenchymal pattern despite an excess of interval cancers and larger screening-detected tumors in this group. These data support the mammographic screening of women with dense parenchymal patterns.
Authors: Karla Kerlikowske; Andrea J Cook; Diana S M Buist; Steve R Cummings; Celine Vachon; Pamela Vacek; Diana L Miglioretti Journal: J Clin Oncol Date: 2010-07-19 Impact factor: 44.544
Authors: Deborah J Rhodes; Carmen Radecki Breitkopf; Jeanette Y Ziegenfuss; Sarah M Jenkins; Celine M Vachon Journal: J Clin Oncol Date: 2015-03-02 Impact factor: 44.544
Authors: Melissa Pilewskie; Emily C Zabor; Elizabeth Gilbert; Michelle Stempel; Oriana Petruolo; Debra Mangino; Mark Robson; Maxine S Jochelson Journal: Breast Cancer Res Treat Date: 2019-01-23 Impact factor: 4.872
Authors: Shereef Elsamany; Abdullah Alzahrani; Seham Abd Elkhalik; Omaima Elemam; Elham Rawah; Mian U Farooq; Musab H Almatrafi; Feras K Olayan Journal: Med Oncol Date: 2014-07-11 Impact factor: 3.064
Authors: Jennifer S Haas; Catherine S Giess; Kimberly A Harris; Julia Ansolabehere; Celia P Kaplan Journal: J Gen Intern Med Date: 2018-08-08 Impact factor: 5.128
Authors: István Pálka; Gyöngyi Kelemen; Katalin Ormándi; György Lázár; Tibor Nyári; László Thurzó; Zsuzsanna Kahán Journal: Pathol Oncol Res Date: 2008-03-06 Impact factor: 3.201
Authors: Monika Nothacker; Volker Duda; Markus Hahn; Mathias Warm; Friedrich Degenhardt; Helmut Madjar; Susanne Weinbrenner; Ute-Susann Albert Journal: BMC Cancer Date: 2009-09-20 Impact factor: 4.430